多发肋骨骨折与连枷胸早期手术稳定与非手术管理相比结局更好
该研究分析美国外科医师学会创伤质量改进项目2017–2021年数据,纳入≥3根钝性肋骨骨折且无重大胸外损伤的成人,采用逆概率治疗加权比较SSRF与风险加权非手术管理(NOM)。加权后SSRF与更低死亡率相关(1.5% vs 2.7%,p<0.001),但住院时间(中位10 vs 5天)和ICU时间(5 vs 3天)更长。连枷胸亚组SSRF死亡率4.2% vs NOM 10.1%(p=0.002),非连枷胸组1.3% vs 2.0%(p=0.003)。82小时内早期SSRF与延迟固定死亡率相似(1.6% vs 1.4%,p=0.647),但早期SSRF与更低ARDS(0.5% vs 1.5%)、呼吸机相关肺炎(0.9% vs 2.3%)和更短住院时间相关。
要点
- 对≥3根钝性肋骨骨折且无重大胸外损伤的成人,加权后SSRF组住院死亡率1.5% vs NOM组2.7%(p<0.001)。
- 连枷胸亚组SSRF死亡率4.2% vs NOM 10.1%(p=0.002),非连枷胸组1.3% vs 2.0%(p=0.003)。
- SSRF组住院时间中位10天 vs NOM 5天,ICU时间5天 vs 3天(均p<0.001),资源利用增加。
- 82小时内早期SSRF与延迟固定死亡率相似(1.6% vs 1.4%,p=0.647),但早期SSRF的ARDS 0.5% vs 1.5%、VAP 0.9% vs 2.3%,住院时间更短。
- 证据等级为治疗/护理管理Level III。
适用人群与场景
- 成人(美国外科医师学会创伤质量改进项目2017–2021年数据),≥3根钝性肋骨骨折且无重大胸外损伤。
- 亚组分析包括连枷胸和非连枷胸患者。
研究设计与关键结果
- 研究类型:基于美国外科医师学会创伤质量改进项目2017–2021年数据的分析,采用逆概率治疗加权比较SSRF与风险加权NOM。
- 样本量:SSRF组3806例,加权对照(NOM)组3753例。
- 主要终点:加权后SSRF组住院死亡率1.5% vs NOM组2.7%(p<0.001)。
- 次要终点:SSRF组住院时间中位10天 vs NOM 5天,ICU时间中位5天 vs 3天(均p<0.001)。
- 连枷胸亚组:SSRF死亡率4.2% vs NOM 10.1%(p=0.002);非连枷胸组SSRF 1.3% vs NOM 2.0%(p=0.003)。
- 时机分析:82小时内早期SSRF与延迟固定死亡率相似(1.6% vs 1.4%,p=0.647);早期SSRF与更低ARDS(0.5% vs 1.5%)、VAP(0.9% vs 2.3%)和更短住院时间相关。
证据类型、等级与局限
- 证据类型:基于全国性创伤数据库的治疗/护理管理研究;证据等级Level III。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对≥3根钝性肋骨骨折且无重大胸外损伤的成人,SSRF与更高生存相关,尤其连枷胸患者,但需预期住院和ICU资源利用增加。
- 82小时内早期SSRF与延迟固定死亡率相似,但与更低ARDS、VAP和更短住院时间相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Surgical stabilization of rib fractures (SSRF) is increasingly performed. Nationwide data comparing its outcomes with nonoperative management (NOM) and defining the best timing for SSRF are scarce.
METHODS: We analyzed data from the American College of Surgeons Trauma Quality Improvement Program, 2017-2021. Adults with three or more blunt rib fractures and no major extrathoracic injury were included. Surgical fixation was compared with risk-weighted NOM using inverse probability of treatment weighting. Primary outcome was in-hospital mortality. Secondary outcomes were hospital and intensive care length of stay, ventilator duration, ventilator-free days, acute respiratory distress syndrome, and ventilator-associated pneumonia. Subgroup analyses examined flail chest and the impact of timing of fixation, which was modeled as a continuous exposure with a generalized additive spline; its discriminatory performance was evaluated with receiver-operating-characteristic curve analysis to calculate the Youden's index.
RESULTS: A total of 3,806 patients underwent SSRF, and 3,753 weighted controls received NOM. After weighting, an association of SSRF with lower mortality (1.5% vs. 2.7%, p < 0.001) but longer hospital (median, 10 vs. 5 days) and intensive care stays (5 vs. 3 days, both p < 0.001) were observed. In the flail chest subgroup, SSRF was associated with a mortality of 4.2% compared with 10.1% with NOM ( p = 0.002). In the nonflail group, mortality was 1.3% after SSRF versus 2.0% in NOM ( p = 0.003). Early SSRF within 82 hours had similar mortality to delayed fixation (1.6% vs. 1.4%, p = 0.647). However, early SSRF was associated with lower rates of acute respiratory distress syndrome (0.5% vs. 1.5%), ventilator-associated pneumonia (0.9% vs. 2.3%), and shorter hospital stays compared with delayed SSRF.
CONCLUSION: Nationwide data demonstrated that SSRF is associated with higher survival, particularly in patients with flail chest, at the cost of increased resource utilization. Surgical stabilization of rib fractures performed within 82 hours is associated with higher survival, lower pulmonary morbidity, and additional resource utilization.
LEVEL OF EVIDENCE: Therapeutic/Care Management; Level III.
参考来源
- Kwon J, Zakhary B, Coimbra BC, et al. Early surgical stabilization of multiple rib fractures and flail chest is associated with better outcomes compared with nonoperative management. J Trauma Acute Care Surg. 2025. PMID: 40828411. doi:10.1097/TA.0000000000004770
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。